COPENHAGEN - Bavarian Nordic A/S (OMX:CSE:BAVA) shares fell 10% after the Danish vaccine maker reported preliminary 2024 results and provided 2025 guidance that failed to impress investors. The ...

Bavarian Nordic’s stock dropped around 10% on the Danish stock exchange Tuesday after reporting disappointing 2024 sales ...

Travel Health business demonstrated strong growth of 22%.Additional mpox vaccine orders during outbreak drove higher revenues ...

Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing ...

If authorised, Vimkunya would be the first vaccine in the EU to protect adolescents aged 12 to 17 against Chikungunya.

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old.The virus-like particle (VLP) single-dose chikungunya ...

Bavarian Nordic A/S COPENHAGEN, Denmark, January 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on January 9, 2025, has ...

Travel Health business demonstrated strong growth of 22%.Additional mpox vaccine orders during outbreak drove higher revenues for the Public Preparedness business and also secured a strong foundation ...

COPENHAGEN, Denmark, January 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA ...

Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on January 9, ...

Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to ...